{
  "id": "5e3a6e70b5b409ea53000018",
  "type": "factoid",
  "question": "What is the target of a drug pidilizumab?",
  "ideal_answer": "Pidilizumab is a a humanised monoclonal antibody that targets programmed death-1 pathway.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26581237",
    "http://www.ncbi.nlm.nih.gov/pubmed/24771328",
    "http://www.ncbi.nlm.nih.gov/pubmed/29143272",
    "http://www.ncbi.nlm.nih.gov/pubmed/26513491",
    "http://www.ncbi.nlm.nih.gov/pubmed/24892254",
    "http://www.ncbi.nlm.nih.gov/pubmed/25965365",
    "http://www.ncbi.nlm.nih.gov/pubmed/25999597",
    "http://www.ncbi.nlm.nih.gov/pubmed/26394770",
    "http://www.ncbi.nlm.nih.gov/pubmed/26248256",
    "http://www.ncbi.nlm.nih.gov/pubmed/26647898",
    "http://www.ncbi.nlm.nih.gov/pubmed/24917416",
    "http://www.ncbi.nlm.nih.gov/pubmed/25056108",
    "http://www.ncbi.nlm.nih.gov/pubmed/24127452",
    "http://www.ncbi.nlm.nih.gov/pubmed/24332512"
  ],
  "snippets": [
    {
      "text": "We present results from the first study to evaluate the immune modulating antibody MDV9300 (pidilizumab) in pediatric patients with DIPG. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143272",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This has prompted multiple large ongoing phase III trials with the expectation for fast-track FDA approvals to satisfy unmet medical needs. Compounds targeting the programmed death-1 pathway that are in clinical trials fall into two major categories, namely antiprogrammed death-1 antibodies: Nivolumab, MK-3475, and pidilizumab; and antiprogrammed death-ligand 1 antibodies: MPDL3280A, BMS-936559, MEDI4736, and MSB0010718C. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24917416",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab, pembrolizumab (formerly known as MK-3475 and lambrolizumab), and pidilizumab are anti-PD-1 antibodies in clinical development for melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancers, lymphoma, and several other cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25965365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25999597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: Recent studies have evaluated the prevalence and prognostic implications of PD-1, PD-L1/2 expression in various lymphoma subtypes. We present an overview of the clinical trials evaluating pidilizumab, nivolumab, and pembrolizumab in patients with lymphoid malignancies, and highlight some of the more promising agents in this class, currently in development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26248256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: This meta-analysis has been conducted to determine the risk of elevated transaminases associated with immune checkpoint inhibitors use in patients with cancer.METHODS: Studies eligible for our analysis included randomized Phase II and III trials of patients with cancer on ipilimumab, nivolumab, pembrolizumab, tremelimumab and pidilizumab, which describe events of elevated transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26394770",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIM: We performed a meta-analysis of the risk of selected gastrointestinal toxicities associated with immune checkpoint inhibitors.PATIENTS & METHODS: Eligible studies included randomized trials of patients with solid tumors on ipilimumab, nivolumab, pembrolizumab, tremelimumab, pidilizumab and atezolizumab, describing events of diarrhea, vomiting or colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26513491",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There are other perspective immune modulating agents, such as anti-PD\u200a1 antibodies (nivolumab, pembrolizumab, pidilizumab) and anti-PD\u200aL1 antibodies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "High levels of peripheral blood Tregs prior to therapy were associated with decreased progression-free survival in FL patients treated with either chemotherapy or combination immunotherapy that targeted CD20 and PD-1 with monoclonal antibodies rituximab and pidilizumab, respectively. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24771328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies to PD-1 (eg, nivolumab, lambrolizumab, and pidilizumab) and PD-L1 (MPDL3280A and BMS-936559) are in various stages of clinical development. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24892254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We did this phase 2 trial to investigate the activity of pidilizumab, a humanised anti-PD1 monoclonal antibody, with rituximab in patients with relapsed follicular lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24332512",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25056108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There are other perspective immune modulating agents, such as anti-PD\u200a1 antibodies (nivolumab, pembrolizumab, pidilizumab) and anti-PD\u200aL1 antibodies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compounds targeting the programmed death-1 pathway that are in clinical trials fall into two major categories, namely antiprogrammed death-1 antibodies: Nivolumab, MK-3475, and pidilizumab; and antiprogrammed death-ligand 1 antibodies: MPDL3280A, BMS-936559, MEDI4736, and MSB0010718C.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24917416",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolera",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25056108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ", pembrolizumab (formerly known as MK-3475 and lambrolizumab), and pidilizumab are anti-PD-1 antibodies in clinical development for melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancers, lymphoma, and several other cancers. Long-term survi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25965365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies to PD-1 (eg, nivolumab, lambrolizumab, and pidilizumab) and PD-L1 (MPDL3280A and BMS-936559) are in various stages of clinical development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24892254",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "programmed death-1 pathway."
}